Scynexis (SCYX) Retained Earnings (2013 - 2026)
Scynexis' (SCYX) quarterly Retained Earnings came in at $466.0 million in Q2 2026, up 7.55% on a YoY basis from $433.2 million in Q2 2025, and up 4.08% quarter-over-quarter from $447.7 million in Q1 2026.
Analysis
Scynexis (SCYX) Retained Earnings (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Retained Earnings for 14 consecutive years, with $466.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Retained Earnings rose 7.55% year-over-year to $466.0 million; the trailing twelve-month figure through Jun 2026 stood at $466.0 million (up 7.55% YoY), and the FY2025 full-year result was $434.5 million, up 0.68% from the prior year.
- Retained Earnings improved to $466.0 million in Q2 2026 per SCYX's latest filing, from $447.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at $466.0 million in Q2 2026 and bottomed at -$456.2 million in Q1 2023.
- Historically, Retained Earnings has averaged $381.8 million across 5 years, with a median of $429.3 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings slumped 212.97% in 2023, then jumped 194.02% in 2024.
- Over 5 years, Retained Earnings stood at $425.5 million in 2022, then advanced by 0.63% to $428.2 million in 2023, then grew by 0.79% to $431.6 million in 2024, then gained by 0.68% to $434.5 million in 2025, then climbed by 7.24% to $466.0 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $466.0 million, $447.7 million, and $434.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 5.13 Bn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 465.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 465.97 Mn |
| Mar 31, 2026 | 447.69 Mn |
| Dec 31, 2025 | 434.52 Mn |
| Sep 30, 2025 | 433.79 Mn |
| Jun 30, 2025 | 433.24 Mn |
| Mar 31, 2025 | 432.42 Mn |
| Dec 31, 2024 | 431.57 Mn |
| Sep 30, 2024 | 430.59 Mn |
| Jun 30, 2024 | 429.66 Mn |
| Mar 31, 2024 | 428.90 Mn |
| Dec 31, 2023 | 428.17 Mn |
| Sep 30, 2023 | 427.61 Mn |
| Jun 30, 2023 | 426.94 Mn |
| Mar 31, 2023 | -456.20 Mn |
| Dec 31, 2022 | 425.49 Mn |
| Sep 30, 2022 | 425.03 Mn |
| Jun 30, 2022 | 423.72 Mn |
| Mar 31, 2022 | 403.83 Mn |
| Dec 31, 2021 | 400.71 Mn |
| Sep 30, 2021 | 367.82 Mn |